| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Division of Molecular Virology [J. M. J., X-S. C., L. A. D.] and Department of Cell Biology [D. M., L. A. D.], Baylor College of Medicine, Houston, Texas 77030
The p21WAF1/CIP1 cyclin-dependent kinase (cdk) inhibitor is a regulator of the G1-S cell cycle checkpoint. Despite the importance of p21 in cell cycle inhibition, its role as a tumor suppressor is uncertain. p21 mutations are infrequent in human tumors, and p21 null mice exhibit no increased tumor incidence. To ascertain whether p21 could influence tumor formation or progression in the context of other oncogenic stimuli, we crossed p21-deficient mice with mammary tumor susceptible Wnt-1 transgenic mice. The p21+/+, p21+/-, and p21-/- Wnt-1 transgenic female offspring were monitored for mammary tumor incidence and growth rates. p21 status had no effect on the age at which mammary tumors formed. However, p21+/- mammary tumors grew significantly faster than p21+/+ and p21-/- mammary tumors. The increased growth rates were confirmed by mitotic index counts and by BrdUrd labelling assays, indicating that a significantly higher percentage of p21+/- tumor cells were in S phase and mitosis than their p21+/+ and p21-/- counterparts. Moreover, cyclin D1-associated phosphorylation of retinoblastoma protein was significantly increased in p21+/- tumor lysates compared with p21+/+ and p21-/- lysates. These results are consistent with data indicating that reduced levels of p21 can facilitate cyclin/cdk complex formation while enhancing cdk activity. Thus, a reduction of p21 dosage may promote tumor progression in the presence of other oncogenic initiators. The dependence of p21 on prior oncogenic stimuli for its tumor-promoting activities suggests that it may behave as a tumor modifier gene rather than as a tumor suppressor gene.
This article has been cited by other articles:
 |
|
 |
|
  M. Law, E. Forrester, A. Chytil, P. Corsino, G. Green, B. Davis, T. Rowe, and B. Law Rapamycin Disrupts Cyclin/Cyclin-Dependent Kinase/p21/Proliferating Cell Nuclear Antigen Complexes and Cyclin D1 Reverses Rapamycin Action by Stabilizing These Complexes Cancer Res., January 15, 2006; 66(2): 1070 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Jackson, R. W. Engelman, D. Coppola, A. B. Cantor, W. Wharton, and W. J. Pledger p21Cip1 Nullizygosity Increases Tumor Metastasis in Irradiated Mice Cancer Res., June 15, 2003; 63(12): 3021 - 3025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Bearss, R. J. Lee, D. A. Troyer, R. G. Pestell, and J. J. Windle Differential Effects of p21WAF1/CIP1 Deficiency on MMTV-ras and MMTV-myc Mammary Tumor Properties Cancer Res., April 1, 2002; 62(7): 2077 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U-J Gohring, A Bersch, M Becker, W Neuhaus, and T Schondorf p21waf correlates with DNA replication but not with prognosis in invasive breast cancer J. Clin. Pathol., November 1, 2001; 54(11): 866 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Liu, S. Guntuku, X.-S. Cui, S. Matsuoka, D. Cortez, K. Tamai, G. Luo, S. Carattini-Rivera, F. DeMayo, A. Bradley, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint Genes & Dev., June 15, 2000; 14(12): 1448 - 1459. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. T. Scott, N. Morrice, and K. L. Ball Reversible Phosphorylation at the C-terminal Regulatory Domain of p21Waf1/Cip1 Modulates Proliferating Cell Nuclear Antigen Binding J. Biol. Chem., April 6, 2000; 275(15): 11529 - 11537. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
